#South Korea #Seoul #Medical Aesthetics #Hugel Inc. #Q1 Earnings

Hugel Reports Record Q1 Earnings

Hugel Inc., a prominent South Korean company in the medical aesthetics sector, has made headlines with its remarkable first-quarter earnings for the year. Presenting a strong financial performance, Hugel announced a consolidated net sales figure of KRW 116.6 billion, an increase of 29.9% compared to the previous year. In addition, the company reported an operating profit of KRW 47.6 billion and a net profit of KRW 40.6 billion, representing year-on-year growth rates of 22.3% and 31.5%, respectively.

Key Growth Drivers

The success of Hugel in Q1 can primarily be attributed to robust global market growth alongside stability within the domestic market of South Korea. The company experienced a significant rise in overseas sales of both botulinum toxin and dermal fillers, soaring by 46% year-on-year. Particularly notable was the performance across its four key international markets: the United States, China, Europe, and Brazil, collectively generating KRW 21 billion in net sales.

In Korea, despite a competitive landscape in the aesthetics market, the domestic net sales from toxin and dermal fillers reached KRW 26.7 billion. This growth was driven by a well-planned strategy that included expanded seminars for healthcare professionals and focused medical marketing efforts to enhance brand visibility and engage with potential clients.

Product Performance

Breaking down the performance by product category, Hugel saw its botulinum toxin sales surge by a remarkable 60.6% year-on-year, reaching KRW 65.4 billion. The increase was largely fueled by the rise in shipments to the U.S. and Brazil while achieving balanced growth across both the Asia-Pacific region and Europe.

Additionally, sales from dermal fillers and skin boosters increased to KRW 32.1 billion, marking the third consecutive quarter of growth for this category. Hugel’s active marketing strategies particularly bore fruit in Europe, where the dermal filler sales grew by nearly 10%.

The cosmetics and other related products also displayed a strong performance, generating net sales of KRW 19.2 billion and indicating a solid growth of 30.6% year-on-year. As a growing segment, cosmetics now account for approximately 16% of the company's quarterly sales, signifying its potential as a key driver for future expansion.

Strategic Outlook

Looking ahead, Carrie Strom, President and Global CEO of Hugel, expressed optimism regarding the company’s trajectory. 'Our goal is to strengthen our position as not just the top player in Korea but as a leader in the global medical aesthetics arena this year,' she stated. Strom emphasized a commitment to expanding Hugel’s market presence and sustaining the current growth momentum.

Meanwhile, Daniel Chang, CEO of Hugel Korea, pointed to the solid business fundamentals and execution capabilities of the company, reinforcing their strategy to enhance domestic and global marketing approaches while diversifying their product portfolio.

About Hugel

Founded in 2001, Hugel specializes in the production of injectables for skin rejuvenation, including offerings such as botulinum toxin and hyaluronic acid fillers. The company has established a reputation for safety and quality, with a meaningful commitment to innovation and robust medical affairs to advance the medical aesthetics industry. Currently, Hugel has established its presence in around 70 nations and operates nine subsidiaries across key global markets, including North America and Asia.

With a strategic vision of leveraging industry momentum, Hugel is poised for continued growth as it expands its market reach even further globally.